Project Grant R01DA064699
Award Date 9/1/26
Completion Date 6/30/31
Dollars Obligated $602K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Charleston, SC 29425, USA
Similar Awards
- The National Institute on Drug Abuse awarded The Medical University of South Carolina $207,792 on August 1, 2026, to examine sex differences in the endocannabinoid system and their contribution to differential THC-associated reward in individuals with cannabis use disorder. The research employs a multi-modal human laboratory paradigm involving 134 adults with cannabis use disorder. Participants will undergo pharmacogenetic screening to identify endocannabinoid-related genetic polymorphisms in...
- The National Institute on Drug Abuse awarded The Medical University of South Carolina $211,680 under NIDA's Drug Use and Addiction Research Programs (CFDA 93.279) on August 1, 2026. The recipient will conduct mixed-methods research characterizing hemp-derived alternative cannabinoid product use in natural settings. The project comprises two national, decentralized studies: an online survey and a six-month naturalistic ecological momentary assessment study. Research will assess alternative...
- The National Institute on Drug Abuse awarded the Research Foundation For Mental Hygiene, Inc. (operating through its New York State Psychiatric Institute division) $195,804 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279). The award funds a five-year research project examining how cannabis influences nicotine use among young and emerging adults (ages 18–35) who use electronic nicotine delivery systems. The study integrates human laboratory methods with...
- The National Institute on Drug Abuse awarded the University of Southern California $149,766 on August 12, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to investigate simultaneous nicotine, alcohol, and cannabis co-use among young adults. The funded research examines patterns of use, subjective experiences, and consequences of simultaneous substance co-use—defined as using multiple substances close in time so their effects overlap—among approximately 3,860 young adults...
- The National Institute on Drug Abuse awarded the University of California, San Diego $1,468,376 under the Drug Use and Addiction Research Programs (CFDA 93.279) on July 15, 2026, to conduct a prospective study characterizing sex-specific cannabinoid and endocannabinoid biomarkers as predictors of neuropsychological, behavioral, and withdrawal outcomes during cannabis abstinence in emerging adults. The research will recruit 220 participants aged 18–25 (balanced by sex, 64 percent with heavy...
- The National Institute on Drug Abuse awarded the University of Southern California $2.251 million on April 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to develop and pilot-test a brief mobile phone-based intervention addressing prenatal cannabis use. The intervention incorporates motivational enhancement messaging to correct misperceptions about cannabis harms during pregnancy, alongside harm-reduction and cognitive-behavioral skills—including protective...
- This $668,110 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) will fund the development and acceptability testing of a technology-based intervention to reduce cannabis misuse among college students. The project aims to refine an existing intervention that provides information on cannabis products, marketing, laws, and risks to increase young adults' cannabis literacy. The research will involve focus groups with...
- The National Institute on Drug Abuse awarded a $2.199 million Cooperative Agreement to Pleopharma, Inc. on August 15, 2026, to conduct a Phase 3 clinical trial of PP-01, a novel medication-assisted therapy for cannabis withdrawal syndrome in individuals with cannabis use disorder. The award is funded through the Drug Use and Addiction Research Programs (CFDA 93.279). PP-01 combines a partial CB1 agonist with a gabaergic agent administered in a reverse taper-titration regimen designed to mitigate...
- The National Institute on Drug Abuse awarded The Medical University of South Carolina $675,129 on April 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to evaluate an integrated, trauma-focused intervention for adolescents with co-occurring substance use disorders and post-traumatic stress disorder. The funded research will assess the safety, feasibility, and efficacy of Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure adapted for...
- The National Institute on Drug Abuse awarded The Medical University of South Carolina $211,680 on August 1, 2026, under the Drug Use and Addiction Research Programs (CFDA 93.279) to support research investigating neurobiological mechanisms underlying reward-cue associations and relapse-like behavior in substance use disorders. The project, NPAS4+ Neuronal Ensembles: Mechanisms of Reward-Cue Associations and Relapse-Like Behavior, examines how neuronal activity in the nucleus accumbens...